Bristol Myers, J&J halt heart drug trial after interim review

Bristol Myers Squibb and Johnson & Johnson have discontinued a late-stage trial for their experimental blood clot drug, milvexian, in acute coronary syndrome patients after an independent review determined the study was unlikely to meet its primary efficacy goal. This setback caused Bristol Myers shares to fall 5% in premarket trading, with J&J also experiencing a slight dip. Despite this, two other late-stage trials for milvexian, targeting atrial fibrillation and stroke prevention, are continuing, with results expected in 2026.

Analysis

Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ) have ceased a late-stage trial for their experimental blood clot drug, milvexian, in acute coronary syndrome patients. An independent interim analysis concluded the study was unlikely to achieve its primary efficacy goal of preventing repeat heart problems. This negative development led to a 5% premarket decline in BMY shares, while JNJ experienced a slight dip.

Milvexian, a Factor XIa blocker, was positioned as a novel therapy to reduce clotting with lower bleeding risks compared to existing treatments. The trial's failure indicates that, despite its innovative mechanism, it did not demonstrate sufficient additional benefit when combined with standard antiplatelet therapy. No new safety concerns were identified, suggesting the issue was purely related to efficacy.

This discontinuation represents a significant clinical and commercial setback for the BMY-JNJ collaboration, specifically for the acute coronary syndrome indication. However, two other late-stage trials for milvexian, targeting atrial fibrillation and stroke prevention, are continuing, with results anticipated in 2026, offering potential future catalysts for the drug's overall profile.

Key Decisions for Investors

• Investors should re-evaluate Bristol Myers Squibb's pipeline valuation and near-term revenue projections following the discontinuation of the milvexian trial in acute coronary syndrome, evidenced by the 5% premarket share decline.
• Closely monitor the ongoing late-stage trials for milvexian in atrial fibrillation and stroke prevention, with results expected in 2026, as these represent critical future catalysts for the drug's commercial viability.
• Acknowledge that Johnson & Johnson's diversified portfolio likely buffers the impact of this single trial setback more effectively than for Bristol Myers Squibb.